Published in Diagn Pathol on August 13, 2012
Pulmonary metastasis of a papillary thyroid carcinoma and primary lung adenocarcinoma: two coincident carcinomas at the same location. Diagn Pathol (2013) 0.96
The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol (2013) 0.96
Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis. Diagn Pathol (2013) 0.92
Role of Core Needle Biopsy in the Management of Atypia/Follicular Lesion of Undetermined Significance Thyroid Nodules: Comparison with Repeat Fine-Needle Aspiration in Subcategory Nodules. Eur Thyroid J (2015) 0.87
The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol (2013) 0.86
Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. Arthritis Res Ther (2013) 0.84
The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors. Oman Med J (2015) 0.82
The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis. Tumour Biol (2014) 0.82
Cruciferous vegetables consumption and the risk of ovarian cancer: a meta-analysis of observational studies. Diagn Pathol (2014) 0.81
Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol (2014) 0.80
Meta-analyses between 18 candidate genetic markers and overweight/obesity. Diagn Pathol (2014) 0.80
Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer. Diagn Pathol (2013) 0.79
Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions. PLoS One (2015) 0.78
The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms. PLoS One (2015) 0.78
Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol (2017) 0.77
How microgravity changes galectin-3 in thyroid follicles. Biomed Res Int (2014) 0.76
A Pilot Study of Galectin-3, HBME-1, and p27 Triple Immunostaining Pattern for Diagnosis of Indeterminate Thyroid Nodules in Cytology With Correlation to Histology. Appl Immunohistochem Mol Morphol (2015) 0.76
Does tea consumption correlate to risk of fracture? A meta-analysis. Int J Clin Exp Med (2015) 0.76
Tea consumption didn't modify the risk of fracture: a dose-response meta-analysis of observational studies. Diagn Pathol (2014) 0.75
Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules. Balkan Med J (2015) 0.75
Correlations Between Hector Battifora Mesothelial-1 (HBME-1) Expression and Clinical Pathological Characteristics and Prognosis of Osteosarcoma Patients. Med Sci Monit (2017) 0.75
The expression and significance of Gal-3 and MUC1 in colorectal cancer and colon cancer. Onco Targets Ther (2015) 0.75
The Intraoperative Immunohistochemical Staining of CD56 and CK19 Improves Surgical Decision for Thyroid Follicular Lesions. J Pathol Transl Med (2017) 0.75
Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes. Virchows Arch (2013) 0.75
The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms. Appl Immunohistochem Mol Morphol (2016) 0.75
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol (2006) 6.60
Papillary and follicular thyroid carcinoma. N Engl J Med (1998) 4.95
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg (2005) 2.14
Ultrasonography: is it useful in the diagnosis of cancer in thyroid nodules? J Endocrinol Invest (2002) 1.94
Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? Diagn Cytopathol (2004) 1.88
Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol (2001) 1.63
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. Endocr Pathol (2001) 1.53
Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol (2001) 1.43
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology (2005) 1.41
Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol (2005) 1.37
Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol (2004) 1.19
Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology (2002) 1.16
Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol (2010) 1.16
Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer (2005) 1.14
Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol (2006) 1.11
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci (2007) 1.11
Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid (2008) 1.10
Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol (2001) 1.09
Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol (2003) 1.07
Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology (2006) 1.07
The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol (2004) 1.05
Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol (2010) 1.02
Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol (2011) 1.02
The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One (2011) 1.02
Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol (2006) 1.01
Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol (1999) 1.01
Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer (2005) 1.01
Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol (2006) 0.99
Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun (2008) 0.98
Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol (2008) 0.98
HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol (2008) 0.96
Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer (2007) 0.93
Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck (2004) 0.93
Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest (2004) 0.92
Molecular markers in thyroid cancer diagnostics. Surg Clin North Am (2009) 0.92
Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology (2002) 0.91
Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol (2006) 0.91
Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab (2002) 0.90
Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer (2005) 0.90
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol (2003) 0.89
Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol (2009) 0.89
Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol (2002) 0.89
HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J (2003) 0.88
Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol (2005) 0.88
Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol (2002) 0.87
The multiplicity of thyroid nodules and carcinomas. N Engl J Med (2005) 0.87
Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol (2010) 0.87
Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer (2008) 0.86
Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst (2008) 0.86
Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am J Surg Pathol (2003) 0.85
Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Cancer Cytopathol (2010) 0.85
Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery (2005) 0.85
Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch (2005) 0.85
Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes. Histopathology (2002) 0.85
Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest (2005) 0.84
Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res (2009) 0.83
Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol (2006) 0.83
The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest (2009) 0.83
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol (2006) 0.82
Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol (2003) 0.82
Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol (2004) 0.81
Differential expression of S100C in thyroid lesions. Int J Surg Pathol (2004) 0.81
Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch (2004) 0.81
Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Pol J Pathol (2003) 0.80
Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol (2008) 0.80
HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res (2005) 0.80
Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy. J Otolaryngol Head Neck Surg (2009) 0.80
Expression of cytokeratin 19 and protein p63 in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol (2008) 0.80
Hyalinizing trabecular tumor and papillary carcinoma of the thyroid. Chin Med J (Engl) (2010) 0.79
Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up. Diagn Pathol (2012) 0.79
Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg (2010) 0.79
Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2008) 0.78
Galectin-3 cytotest in thyroid follicular neoplasia: a prospective, monoinstitutional study. Acta Cytol (2009) 0.77
[Ultrasonographic evaluation of thyroid nodules: comparison with cytologic and histologic diagnosis]. Arq Bras Endocrinol Metabol (2004) 0.77
CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid (2010) 0.77
Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Pathobiology (2005) 0.77
[Biological markers in thyroid tumors]. Arq Bras Endocrinol Metabol (2004) 0.76
Cancer-related fatigue: a review. Rev Assoc Med Bras (2011) 1.73
Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights (2010) 1.69
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol (2012) 1.39
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol (2009) 1.09
Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med (2011) 1.07
New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma. Photomed Laser Surg (2006) 1.03
Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol (2012) 0.99
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol (2010) 0.95
Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol (2010) 0.93
Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia (2007) 0.91
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
Dynamic sentinel node biopsy for inguinal lymph node staging in patients with penile cancer: a systematic review and cumulative analysis of the literature. Ann Surg Oncol (2011) 0.89
Management of advanced prostate cancer. Rev Assoc Med Bras (2008) 0.87
Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer (2010) 0.85
Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer (2009) 0.85
[Analysis of delays in diagnosis and treatment of breast cancer patients at a public hospital]. Rev Assoc Med Bras (2008) 0.85
Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors. Sao Paulo Med J (2009) 0.83
Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat (2004) 0.82
Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. Clin Genitourin Cancer (2011) 0.81
The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials. Contemp Clin Trials (2012) 0.81
Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue. BJU Int (2013) 0.81
Quality of internet information available to patients on websites in Portuguese. Rev Assoc Med Bras (2012) 0.81
Increased serum CA-125 levels in patients with lung cancer post thoracotomy. South Med J (2009) 0.80
Interventional procedures for cancer pain management. Einstein (Sao Paulo) (2013) 0.80
[Incidence of the burnout syndrome among Brazilian cancer physicians]. Rev Assoc Med Bras (2006) 0.80
[Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actions]. Rev Assoc Med Bras (2004) 0.79
Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol (2007) 0.79
Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol (2002) 0.78
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori (2011) 0.78
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer (2011) 0.78
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anticancer Drugs (2015) 0.77
Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer (2007) 0.77
Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer (2013) 0.77
Experience with the ABC Foundation School of Medicine undergraduate meeting. Rev Assoc Med Bras (2010) 0.77
Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine. J Pharm Pharmacol (2010) 0.77
Formal statistical testing and inference in randomized phase II trials in medical oncology. Am J Clin Oncol (2013) 0.76
Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer (2014) 0.75
Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. Case Rep Oncol (2013) 0.75
Treatment of breast cancer patients from a public healthcare system in a private center: costs of care for a pilot public-private partnership in oncology. Einstein (Sao Paulo) (2013) 0.75
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2013) 0.75
Paullinia cupana for control of hot flashes in breast cancer patients: a pilot study. Einstein (Sao Paulo) (2013) 0.75
[The training the physician and the communication of a patient's death to family members]. Rev Assoc Med Bras (2005) 0.75
[Prospective evaluation of clinical and Doppler ultrasound characteristics of cancer patients with suspicion of deep venous thrombosis]. Rev Assoc Med Bras (2006) 0.75
[How to consent without understanding?]. Rev Assoc Med Bras (2009) 0.75
A medical student-staffed outpatient oncology clinic: a 10-year Brazilian experience. J Cancer Educ (2008) 0.75
[A new paradigm for the treatment of cancer]. Rev Assoc Med Bras (2004) 0.75
Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial. Acta Haematol (2006) 0.75
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas. Sao Paulo Med J (2008) 0.75
[Professional or household performance of patients with breast cancer undergoing chemotherapy]. Rev Assoc Med Bras (2009) 0.75
Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial. Acta Haematol (2004) 0.75
Uncaria tomentosa (cat's claw) improves quality of life in patients with advanced solid tumors. J Altern Complement Med (2014) 0.75
[Metastatic melanoma of the gallbladder mimicking Bladder Calculi]. Rev Assoc Med Bras (2005) 0.75
Does Time-to-Chemotherapy Impact the Outcomes of Resected Ovarian Cancer? Meta-analysis of Randomized and Observational Data. Int J Gynecol Cancer (2017) 0.75
[Absolute number or lymphonodal quotient: which is the best prognostic factor for women with breast neoplasms? ]. Rev Assoc Med Bras (2006) 0.75
[Clinical research conducted by medical students: its potential for learning and the national scientific production]. Rev Assoc Med Bras (2006) 0.75
Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. J Pain Symptom Manage (2012) 0.75